腦深部電刺激術（DBS）對神經科及精神科藥品市場產生什麼樣的影響？

本報告已在2011年12月21日停止出版。

簡介

目錄

Abstract

Introduction

Deep brain stimulation (DBS) is currently approved only to treat Parkinson's disease and Parkinson-like symptoms; however, clinical trials are under way for DBS in several other neurological and psychiatric disorders. As these surgical interventions gain acceptance in the face of conventional therapies' shortcomings in severely affected patients, opportunities are emerging for such devices, used both alone and in conjunction with existing drug regimens.

Get the Answers You Need to Shape Your Strategy

Currently, DBS is approved only for parkinsonism. For what other indications is DBS being investigated? What advantages does DBS offer to treat these indications? What potential exists for DBS in these indications? The risk factors associated with DBS have made it a last-resort therapy for most indications. How competitive will DBS be with conventional drug therapies? In which indications will it stand out? Will DBS ever be used as an early therapy, in any indication? Medtronic is the only company to have an approved device for DBS, although several companies have devices in development for other indications. Which of the companies developing DBS devices is best positioned to succeed in these new markets? What innovations must these companies provide to ensure success? Which company is poised to collaborate with drugmakers in creating a viable combination therapy?

Table of Contents

• Executive Summary
• Strategic Implications
• Stakeholder Implications
• Introduction
• Overview of DBS
• DBS for Specific Therapeutic Areas
• Parkinson's Disease
• Epilepsy
• Psychiatric Disorders: OCD and Depression
• Headaches
• Companies Developing DBS Systems
• Medtronic
• NeuroPace
• Cyberonics
• Boston Scientific
• Medtrode
• Advanced Neuromodulation Systems
• Impact of DBS on Drug Markets
• Market Implications
• DBS and the PD Market
• DBS and the Epilepsy Market
• DBS and the Psychiatric Markets
• DBS and the Headache Market
• Codevelopment of Pharmacological Agents and DBS
• Outlook for DBS in the Marketplace
• Bibliography

Tables

• 1. Brain Regions Implicated in Epileptic Seizures
• 2. Companies Developing DBS Devices

Figures

• 1. Regions of the Brain Targeted for Deep Brain Stimulation
• 2. Schematic of Deep Brain Stimulation
• 3. Growth of DBS Procedures, by Indication, 2005-2015

相關商品

精神病相關市場調查報告書

抗精神病藥物市場(∼2017年):金普薩(Zyprexa)·安立復(Abilify)·思樂康(Seroquel)·哲思(Geodon)專利到期，及學名藥開始販售將限制開發平台分子商業機會的可能性
Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules
價格 : US $ 3500
出版日期 : 2012年01月

阿茲海默症：新藥・市場・企業
Alzheimer disease - new drugs, markets and companies
價格 : US $ 3500
出版日期 : 2012年01月

憂鬱症:針對二線患者的新一代產品競爭
Product Profiles: Depression - Next generation vies for second-line patients
價格 : US $ 11400
出版日期 : 2011年11月

Decision Resources, Inc.發行的製藥相關市場調查報告書

傳染病疫苗開發平台:競爭檢討

Special Report: The Infectious Disease Vaccine Pipeline--A Competitive Review

價格 : US $ 9200

出版日期 : 2011年06月

感染疾病疫苗:未滿足需求和對醫藥品產業來說的機會

Special Report: Infectious Disease Vaccines--Unmet Needs and Opportunities for Pharma

價格 : US $ 9200

出版日期 : 2011年06月

自閉症譜系障礙:高未滿足需求創造出很大的市場機會

Special Report: Autism Spectrum Disorders--High Unmet Needs Create Significant Market Opportunities

價格 : US $ 9200

出版日期 : 2011年06月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!